Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

May 14, 2024

https://www.globenewswire.com/news-release/2024/05/14/2881557/0/en/Nurix-Therapeutics-Announces-Upcoming-Oral-Presentation-of-New-Data-from-Ongoing-Clinical-Trial-of-NX-5948-a-Selective-Bruton-s-Tyrosine-Kinase-BTK-Degrader-at-the-European-Hematol.html

Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients

Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations to BTK inhibitors

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.